Forty-eight perennial rhinitis patients completed a six weeks' open trial of intranasal beclomethasone dipropionate aerosol. Each received a daily dose of 400 micrograms. Thirty-five responded excellently, seven reported satisfactory improvement and six failed. This study indicated that patients with a demonstrable allergic component responded favorably. However, due to the wide margin of safety the authors suggest that it be tried on the non-infective perennial rhinitis with no demonstrable allergic component as well.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
In perennial allergic rhinitis, RQLQ is improved similarly by Azelastine 0.15 and mometasone furoate.
World Allergy Organ J
January 2025
Allergy & Asthma Solutions, Coto de Caza, CA, USA.
Unlabelled: Some double-blind, placebo-controlled trials have shown that Azelastine (Aze) high dose (0.15%) was effective in seasonal (SAR) and perennial allergic rhinitis (PAR). However, there was no long-term comparison between Aze 0.
View Article and Find Full Text PDF[Clinical efficacy of sublingual immunotherapy for allergic rhinitis].
Nihon Yakurigaku Zasshi
January 2025
Department of Otolaryngology, Head and Neck Surgery, Graduate School of Medicine, Chiba University.
The prevalence of allergic rhinitis (AR) reached 49.2% in 2019. In particular, the prevalence of Japanese cedar (JC) pollinosis is 38.
View Article and Find Full Text PDF[Development of fast dissolving sublingual immunotherapy tablet enhancing medication accessibility].
Nihon Yakurigaku Zasshi
January 2025
Torii pharmaceutical Co., LTD.
In the overall Japanese population, the prevalence of perennial allergic rhinitis (AR) increased from 18.7% to 24.5% from 1998 to 2019.
View Article and Find Full Text PDFAssociation between allergen-specific immunoglobulin E sensitization, allergic rhinitis symptoms, and quality of life in school-aged children.
Sci Rep
December 2024
Department of Epidemiology and Environmental Medicine, Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, 1110 Shimokato, Chuo, Yamanashi, 409-3898, Japan.
This study aimed to investigate the relationship between allergen-specific immunoglobulin E (IgE) sensitization and allergic rhinitis (AR) symptoms in school-aged children in Japan and to understand the current severity of AR symptoms and the quality of life (QOL) among children with AR. We analyzed data from 8-year-old children who participated in the Yamanashi Adjunct Study of the Japan Environment and Children's Study, focusing on those with complete information on specific IgE levels and AR (1229 for perennial AR [PAR] and 1196 for seasonal AR [SAR]). Sensitization was determined when allergen-specific IgE levels were class 2 (0.
View Article and Find Full Text PDFDouble-Blind, Placebo-Controlled Trial of the Efficacy and Safety of Azelastine Hydrochloride in Children with Perennial Allergic Rhinitis.
Int Arch Allergy Immunol
December 2024
Allergy & Asthma Solutions, Coto de Caza, California, USA.
Introduction: Allergic rhinitis (AR) affects up to 40% of the pediatric population. The US practice parameter recommends the use of intranasal antihistamines (INAH) or INCS as first-line therapy for the treatment of AR. Although not directly targeted to children, the recent US practice parameters proposed INAH as first-line therapy whereas the ARIA guidelines did not.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!